Navigation Links
Celsion Corporation Reports First Quarter 2013 Financial Results and Provides Business Update
Date:5/9/2013

LAWRENCEVILLE, N.J., May 9, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the first quarter ended March 31, 2013 and provided a business update on its clinical trials of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.  ThermoDox® is being evaluated in a global, multi-center Phase III clinical trial (the HEAT Study) in patients with non-resectable hepatocellular carcinoma (HCC), also known as primary liver cancer.  ThermoDox® is also being evaluated in a Phase II trial for patients with recurrent chest wall breast cancer, The DIGNITY Study.

Following the announcement on January 31, 2013, that ThermoDox® in combination with radiofrequency ablation (RFA) did not meet the HEAT Study's primary endpoint, the Company conducted a comprehensive analysis of the data from the Study which was reviewed by its key principal investigators as well as liver cancer and clinical data experts.  These emerging findings from the HEAT Study suggest that RFA dwell time had a positive impact on progression free survival (PFS) and overall survival (OS) in patients treated with ThermoDox® plus RFA when compared to the control group.  This analysis was conducted in a sizable patient subgroup.  These findings will be discussed by two of the HEAT Study's lead investigators at scientific sessions of the World Conference on Interventional Oncology on May 16, 2013. Celsion's lead investigators agree that these are interesting findings which should be further pursued.

"With the support of our medical advisors, we have been working diligently to better understand the clinical data and findings from the Phase III HEAT Study.  Concurrently, we have been taking appropriate measures to position C
'/>"/>

SOURCE Celsion Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Celsion Corporation to Hold First Quarter 2013 Financial Results Conference Call on Thursday, May 9, 2013
2. Celsion Corporation Provides Business Update
3. Todays Research on Celsion, Zogenix, Actavis, and Avanir Pharma
4. Celsion Corporation Announces $15 Million Registered Direct Offering
5. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
6. ETEX Corporation announces extended Supply Agreement with Knee Creations, LLC
7. Verenium Corporation to Announce First Quarter 2013 Financial Results
8. EMCO High Voltage Corporation to Exhibit at 61st ASMS Conference on Mass Spectrometry and Allied Topics
9. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
10. Techne Corporation Releases Unaudited Third Quarter And Nine Month Fiscal Year 2013 Results
11. Street Named After EMCO High Voltage Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... PureTech , a science and technology development ... today the closing of a $55 million growth ... a $120 Billion group of funds. The funding ... forward and to advance new healthcare related products ... really go for the big ideas that can ...
(Date:10/19/2014)... Latin American hardware encryption display market report defines and ... forecast of revenue. This market was valued at $165.0 ... million by 2018, at a CAGR of 70.3% from ... the Latin American hardware encryption market report to get ... provides a glimpse of the segmentation of the market, ...
(Date:10/19/2014)... October 19, 2014 The Asian Automatic ... Asian with analysis and forecast of revenue. The Automatic ... to around $463.9 million by 2018, at a developing ... through the TOC of the Asian Automatic patient billing ... provided. This also provides a glimpse of the segmentation ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... /PRNewswire-FirstCall/ - Victhom Human Bionics Inc., "Victhom" (TSX:VHB), ... CE Mark approval for its Neurostep(TM) System, the ... used on peripheral nerves. CE Mark represents regulatory ... in any of the Member States of the ...
... NOVATO, Calif., Feb. 3 BioMarin Pharmaceutical Inc. (Nasdaq: ... National Health Surveillance Agency, has granted BioMarin marketing approval ... Mucopolysaccharidosis VI (MPS VI)."We are very pleased to receive ... largest known number of affected MPS VI patients in ...
... 3 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), ... that Jerry McMahon, Ph.D.,chairman and CEO, will present at ... Tuesday, February 10, at 10 a.m. Eastern Time at ... Dr. McMahon will provide a corporate overview, including a ...
Cached Biology Technology:Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 2Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 3Naglazyme Approved by Brazil's National Health Surveillance Agency 2Naglazyme Approved by Brazil's National Health Surveillance Agency 3Naglazyme Approved by Brazil's National Health Surveillance Agency 4Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference 2
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
(Date:10/14/2014)... to produce enough food to feed the world in ... of the United Nations predicts that food production must ... a growing global population, and plants are one major ... Plants—grains, cereals, fruits, vegetables, and more—feed humans directly and ... into our knowledge of how plants work to develop ...
(Date:10/14/2014)... LA JOLLA, CA – October 14, 2014 – Scientists ... $6.6 million from the National Institutes of Health (NIH) ... most prevalent virus-induced hemorrhagic fever disease in Africa. The ... disease and why some patients die, while others survive ... researchers to understand the basic mechanism of how Lassa ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... Bowman Design Group, an integrated marketing and communications design ... the first and only company in the United States ... exhibition and events industry association. Third party verification of ... or exceeded goals set for nine criteria including greenhouse ...
... Greg Asner has been elected to the National Academy ... and 21 foreign associates from 14 countries elected "in ... research." The total number of active members now stands ... the Department of Global Ecology,s first staff scientist. Since ...
... inventory plots in the Northeast and Midwestern United States contain ... Service study found. The study across two dozen states from ... on the landscape where invasive plants might take root. ... annual forest inventory had at least one introduced species, but ...
Cached Biology News:Bowman Design Group is first US company awarded German FAMAB 'Sustainable Company' certification 2Carnegie's Greg Asner elected to National Academy of Sciences 2In the Northeast, forests with entirely native flora are not the norm 2